Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A single arm phase 2 study of enzastaurin in combination with erlotinib, both administered orally daily, to patients with advanced non-small cell lung cancer (NSCLC) Wakelee, H. A., Dubey, S., Krupitskaya, Y., Osarogiagbon, R. U., Sanborn, R. E., Bernstein, E. D., Dudek, A. Z., Latz, J. E., Yuan, Z., Natale, R. B. LIPPINCOTT WILLIAMS & WILKINS. 2009: S445–S445
View details for Web of Science ID 000269496001254